WuXi Biologics (02269) surged over 3% during trading session. As of press time, the stock was up 2.53% to HK$31.54 with trading volume reaching HK$836 million.

On the news front, according to WuXi Biologics' official announcement on August 12, the company declared that its ultra-high efficiency continuous perfusion production technology platform WuXiUP™ has successfully completed pilot-scale end-to-end fully automated continuous drug substance production. The platform will be further deployed across major GMP manufacturing facilities to empower clients with more efficient and flexible technological capabilities, accelerating the entire process from biologics development to commercialization.

According to the introduction, the WuXiUP™ fully automated continuous production line integrates automated systems throughout the entire process, enabling 24/7 uninterrupted high-efficiency operations while significantly reducing manual intervention, minimizing product quality risks, and enhancing production efficiency. The WuXiUP™ upstream process achieved a total yield exceeding 110 g/L during 24 days of continuous cell culture, with maximum daily productivity reaching 7.6 g/L, positioning it at the forefront among similar processes. In the downstream process, the platform incorporates two-step high-efficiency membrane chromatography technology, which offers faster mass transfer compared to traditional resin-based materials, delivering a breakthrough 5-10 fold capacity improvement.